Overview

Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Status:
Recruiting
Trial end date:
2024-12-16
Target enrollment:
Participant gender:
Summary
The treatment regimen will consist of 4 doses of 225Ac-PSMA-I&T
Phase:
Phase 2
Details
Lead Sponsor:
Excel Diagnostics and Nuclear Oncology Center